[go: up one dir, main page]

KR960704038A - 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek) - Google Patents

세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)

Info

Publication number
KR960704038A
KR960704038A KR1019960700834A KR19960700834A KR960704038A KR 960704038 A KR960704038 A KR 960704038A KR 1019960700834 A KR1019960700834 A KR 1019960700834A KR 19960700834 A KR19960700834 A KR 19960700834A KR 960704038 A KR960704038 A KR 960704038A
Authority
KR
South Korea
Prior art keywords
hek
seq
dna
polypeptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019960700834A
Other languages
English (en)
Inventor
엠. 패트리샤 베크만
더글라스 피. 세레티
Original Assignee
크리스토퍼 엘. 와이트
임뮤넥스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 엘. 와이트, 임뮤넥스 코포레이션 filed Critical 크리스토퍼 엘. 와이트
Publication of KR960704038A publication Critical patent/KR960704038A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Secondary Cells (AREA)

Abstract

본 발명은 hek 리간드(hek-L) 폴리펩티드 및 DNA 서열, 및 hek-L 폴리펩티드를 제공하는데 유용한 벡터 및 형질전환된 숙주 세포에 관한 것이다.
hek-L 폴리 펩티드는 수용체 티로신 키나제군의 성분인 세포 표면 수용체(hek)에 결합한다.
hek는 특정 종양 세포주를 포함하는 세포에서 발현된다. hek-L 폴리펩티드는 또한 elk로 공지되어 있는 개개 수용체 티로신 키나제에 결합한다.

Description

세포 표면 수용체 Hek와 결합하는 사이토킨 (Cytokines That Bind the Cell Surface Receptor Hek)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 서열 확인 번호 1의 뉴클레오티드 83-796, 83-745, 140-796 및 140-745로 이루어지는 군 중에서 선택된 서열과 80% 이상의 일치성을 갖는 뉴클레오티드 서열을 포함하는, hek와 결합할 수 있는 hek-L 단백질을 코딩하는 단리된 DNA.
  2. 제1항에 있어서, 상기 DNA가 서열 확인 번호 1의 뉴클레오티드 83-796, 83-745, 140-796 및 140-745로 이루어지는 군 중에서 선택된 뉴클레오티드 서열을 포함하는 것인 단리된 DNA.
  3. 서열 확인 번호 3의 뉴클레오티드 28-630, 28-573, 94-630 및 94-573으로 이루어지는 군 중에서 선택된 서열과 80% 이상의 일치성을 갖는 뉴클레오티드 서열을 포함하는, hek와 결합할 수 있는 hek-L 단백질을 코딩하는 단리된 DNA.
  4. 제3항에 있어서, 상기 DNA가 서열 확인 번호 3의 뉴클레오티드 28-630, 28-573, 94-630 및 94-573으로 이루어지는 군 중에서 선택된 뉴클레오티드 서열을 포함하는 것인 단리된 DNA.
  5. 서열 확인 번호 2의 아미노산 1-202 및 1-219 및 서열 확인 번호 4의 아미노산 1-160 및 1-179로 이루어지는 군 중에서 선택된 서열과 80% 이상의 일치성을 갖는 아미노산 서열을 포함하고 hek와 결합할 수 있는 인체 hek-L 단백질을 코딩하는 단리된 DNA.
  6. 제5항에 있어서, 상기 hek-L이 서열 확인 번호 2의 아미노산 1-202 및 1-219및 서열 확인 번호 4의 아미노산 1-160 및 1-179로 이루어지는 군 중에서 선택된 아미노산 서열을 포함하는 것인 단리된 DNA.
  7. 서열 확인 번호 2의 아미노산 1-202 및 서열 확인 번호 4의 아미노산 1-160으로 이루어지는 군 중에서 선택된 서열과 80% 이상의 일치성을 갖는 아미노산 서열을 포함하는 hek-L 및 Fc 폴리펩티드를 포함하는 융합 단백질을 코딩하는 단리된 DNA.
  8. 제1항에 따른 DNA를 포함하는 발현 벡터.
  9. 제3항에 따른 DNA를 포함하는 발현 벡터.
  10. 제5항에 따른 DNA를 포함하는 발현 벡터.
  11. 제7항에 따른 DNA를 포함하는 발현 벡터.
  12. 제8항에 따른 벡터로 형질전환된 숙주 세포를 hek-L의 발현을 촉진시키는 조건 하에서 배양하고, 이 배양물로부터 hek-L 폴리펩티드를 회수하는 것으로 이루어지는, hek-L 폴리펩티드의 제조 방법.
  13. 제9항에 따른 벡터로 형질전환된 숙주 세포를 hek-L의 발현을 촉진시키는 조건 하에서 배양하고, 이 배양물로부터 hek-L 폴리펩티드를 회수하는 것으로 이루어지는, hek-L 폴리펩티드의 제조 방법.
  14. 제10항에 따른 벡터로 형질전환된 숙주 세포를 hek-L의 발현을 촉진시키는 조건하에서 배양하고, 이 배양물로부터 hek-L 폴리펩티드를 회수하는 것으로 이루어지는, hek-L 폴리펩티드의 제조 방법.
  15. 제11항에 따른 벡터로 형질전환된 숙주 세포를 hek-L의 발현을 촉진시키는 조건 하에서 배양하고, 이 배양물로 부터 hek-L 폴리펩티드를 회수하는 것으로 이루어지는, hek-L 폴리펩티드의 제조 방법.
  16. N-말단 아미노산 서열 Leu-Leu-Ala-Gln-Gly-Pro-Gly-Gly-Ala-Leu-Gly-Asu을 갖는 것을 특징으로 하는, hek와 결합할 수 있는 정제된 성숙 인체 hek-L 단백질.
  17. 제16항에 있어서, 상기 hek-L이 서열 확인 번호 2의 아미노산 1-202 및 1-219로 이루어지는 군 중에서 선택된 아미노산 서열을 포함하는 것인 정제된 hek-L 단백질.
  18. N-말단 아미노산 서열 Gly-Ser-Ser-Leu-Arg-His-Val-Val-Tyr-Trp-Asn-Ser을 갖는 것을 특징으로 하는, hek와 결합할 수 있는 정제된 성숙 인체 hek-L 단백질.
  19. 제18항에 있어서, 상기 hek-L이 서열 확인 번호 4의 아미노산 1-160 및 1-179로 이루어지는 군 중에서 선택된 아미노산 서열을 포함하는 것인 정제된 hek-L 단백질.
  20. 제5항에 따른 DNA에 의해 코딩된 정제된 hek-L 단백질.
  21. (a) 서열 확인 번호 2의 1 내지 x 아미노산 (여기서, x는 서열 확인 번호 2의 제193 내지 제219 위치의 아미노산임), 및 (b) 서열 확인 번호 4의 1 내지 y의 아미노산 (여기서, y는 서열 확인 변호 4의 제147 내지 제179 위치의 아미노산임)으로 이루어지는 군 중에서 선택된 아미노산 서열을 포함하는 정제된 hek-L 폴리펩티드.
  22. ATCC 69384로 기탁된 형질전환된 세포 및 ATCC 69395로 기탁된 형질전환된 세포로 이루어지는 군 중에서 선택된 형질전환된 세포에 함유되어 있는 재조합 벡터의 hek-L cDNA 인서트에 의해 코딩된 hek-L 단백질.
  23. 제7항에 따른 DNA에 의해 코딩되는 융합 단백질.
  24. 제20항에 따른 hek-L 단백질 또는 이 hek-L의 면역원 단편과 면역반응성의 항체.
  25. 제24항에 있어서, 상기 항체가 단일 클론 항체인 항체.
  26. 제2항에 따른 DNA 서열 또는 그의 DNA 또는 RNA 보체의 뉴클레오티드 약 14개 이상으로 된 서열을 포함하는 단리된 핵산 분자.
  27. 제4항에 따른 DNA 서열 또는 그의 DNA 또는 RNA 보체의 뉴클레오티드 약 14개 이상으로 된 서열을 포함하는 단리된 핵산 분자.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700834A 1993-08-20 1994-08-17 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek) Withdrawn KR960704038A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10974593A 1993-08-20 1993-08-20
US19745 1993-08-20
US11442693A 1993-08-30 1993-08-30
US114426 1993-08-30
US16113293A 1993-12-03 1993-12-03
US161132 1993-12-03
US08/240,124 US5516658A (en) 1993-08-20 1994-05-09 DNA encoding cytokines that bind the cell surface receptor hek
US240124 1994-05-09
PCT/US1994/009282 WO1995006065A1 (en) 1993-08-20 1994-08-17 Cytokines that bind the cell surface receptor hek

Publications (1)

Publication Number Publication Date
KR960704038A true KR960704038A (ko) 1996-08-31

Family

ID=27493708

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700834A Withdrawn KR960704038A (ko) 1993-08-20 1994-08-17 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)

Country Status (15)

Country Link
US (5) US5516658A (ko)
EP (1) EP0804482B1 (ko)
JP (2) JP3699477B2 (ko)
KR (1) KR960704038A (ko)
AT (1) ATE259377T1 (ko)
AU (1) AU680540B2 (ko)
CA (1) CA2169851A1 (ko)
DE (1) DE69433552T2 (ko)
DK (1) DK0804482T3 (ko)
ES (1) ES2216000T3 (ko)
FI (1) FI960743A0 (ko)
NO (1) NO960652D0 (ko)
NZ (1) NZ271878A (ko)
PT (1) PT804482E (ko)
WO (1) WO1995006065A1 (ko)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258697A (en) * 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
DE69529674T3 (de) * 1994-04-04 2007-06-28 Regeneron Pharmaceuticals, Inc. Biologisch aktive liganden der eph-familie
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
USRE37582E1 (en) 1994-10-05 2002-03-12 Immunex Corporation Cytokine designated LERK-6
US5919905A (en) * 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
ES2277335T3 (es) 1994-10-05 2007-07-01 Immunex Corporation Citoquina designada lerk-6.
WO1998001548A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
AUPO754997A0 (en) * 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
US20030198951A1 (en) * 1999-12-02 2003-10-23 David Mack Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20030092035A1 (en) * 2000-05-04 2003-05-15 Anderson David J. Pain signaling molecules
US6593110B2 (en) * 2000-05-04 2003-07-15 California Institute Of Technology Checkpoint-activating oligonucleotides
US7348406B2 (en) * 2001-01-16 2008-03-25 Serono Genetics Institute S.A. Metabolic gene polynucleotides and polypeptides and uses thereof
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
CA2522082A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
EP1788088B1 (en) * 2004-07-27 2009-05-27 Riken Vector expressing human n-deacetylase/n-sulfotransferase 2
WO2006081418A2 (en) * 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US9223751B2 (en) * 2006-09-22 2015-12-29 Intel Corporation Performing rounding operations responsive to an instruction
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
HRP20171741T1 (hr) 2007-08-21 2017-12-29 Amgen, Inc Proteini koji se vežu na ljudski antigen c-fms
US9320812B2 (en) 2010-12-08 2016-04-26 Stemcentrx, Inc. Modulators and methods of use
AU2012230896B9 (en) 2011-03-23 2015-06-18 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
UA126115C2 (uk) 2016-03-08 2022-08-17 Янссен Байотек, Інк. Антитіло до gitr
EP3484499A4 (en) 2016-07-14 2020-05-13 Scholar Rock, Inc. TGFB ANTIBODIES, METHODS AND USE
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2019262599B2 (en) 2018-05-04 2023-10-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3898592B1 (en) 2018-12-20 2024-10-09 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US20220073504A1 (en) 2018-12-20 2022-03-10 Amgen Inc. Kif18a inhibitors
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
AU2020232242A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es) 2019-05-21 2022-01-04 Amgen Inc Formas en estado solido.
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
AU2020326627A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021071979A1 (en) * 2019-10-08 2021-04-15 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing epithelial barrier function
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
JP2023515235A (ja) 2019-10-31 2023-04-12 大鵬薬品工業株式会社 ４－アミノブタ－２－エンアミド誘導体及びその塩
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
CN114728960B (zh) 2019-11-14 2025-05-27 美国安进公司 Kras g12c抑制剂化合物的改善的合成
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
TW202216151A (zh) 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN118234731A (zh) 2021-05-05 2024-06-21 锐新医药公司 Ras抑制剂
CA3217920A1 (en) 2021-05-05 2022-11-10 Andreas BUCKL Ras inhibitors for the treatment of cancer
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
KR20250022133A (ko) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. 거대고리 ras 억제제
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202515582A (zh) 2023-08-24 2025-04-16 日商大塚製藥股份有限公司 西區嘧啶(cedazuridine)之固定劑量組合
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0553287A4 (en) * 1990-10-16 1994-06-08 Univ Michigan Cytokine-induced marker for inflammatory response
JPH04224527A (ja) * 1990-12-25 1992-08-13 Daikin Ind Ltd ペンタフルオロジクロロプロパンの製造方法
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
ATE278019T1 (de) * 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
NZ258697A (en) * 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
CA2149333C (en) * 1992-11-13 2002-01-22 Timothy D. Bartley Eck receptor ligands
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek

Also Published As

Publication number Publication date
AU7567594A (en) 1995-03-21
EP0804482A1 (en) 1997-11-05
EP0804482A4 (en) 2001-05-16
US20020010325A1 (en) 2002-01-24
CA2169851A1 (en) 1995-03-02
FI960743A7 (fi) 1996-02-19
JP3699477B2 (ja) 2005-09-28
US6274117B1 (en) 2001-08-14
ES2216000T3 (es) 2004-10-16
ATE259377T1 (de) 2004-02-15
NO960652L (no) 1996-02-19
DE69433552D1 (de) 2004-03-18
EP0804482B1 (en) 2004-02-11
FI960743L (fi) 1996-02-19
US6949366B2 (en) 2005-09-27
DK0804482T3 (da) 2004-06-07
FI960743A0 (fi) 1996-02-19
WO1995006065A1 (en) 1995-03-02
DE69433552T2 (de) 2004-12-16
JP2004187689A (ja) 2004-07-08
US5516658A (en) 1996-05-14
US5969110A (en) 1999-10-19
NO960652D0 (no) 1996-02-19
NZ271878A (en) 1997-10-24
JPH09502174A (ja) 1997-03-04
JP3786944B2 (ja) 2006-06-21
PT804482E (pt) 2004-06-30
US5738844A (en) 1998-04-14
AU680540B2 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
CA2309783A1 (en) Fibroblast growth factor-19
CA2225378A1 (en) Cytokine that induces apoptosis
JP2003532365A5 (ko)
CA2179909A1 (en) Ligand that binds fas antigen
NZ336929A (en) Purified receptor that binds TRAIL and antibodies thereof
CA2289912A1 (en) Human receptor proteins; related reagents and methods
CA2318482A1 (en) Il-18 receptors
JP2002508183A5 (ko)
KR960705041A (ko) Tgf 수용체 족 및/ 또는 bmp 수용체 족에 속하는 액티빈 수용체 유사 키나제(alk) (activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family)
RU2003106809A (ru) Гены гомологичных иммунодоминантных белков ehrlichia canis в 28-килодальтон и их применение
CA2144056A1 (en) Cd27 ligand
CA2153507A1 (en) A fas ligand, a fragment thereof and dna encoding the same
JP2002502589A5 (ko)
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
CA2188279A1 (en) Interleukin-15 receptors
KR950704489A (ko) 인터페론 타우 조성물 및 사용방법(interferon tau compositions and methods of use)
CA2295308A1 (en) Isolated dendritic cell membrane protein genes
CA2273196A1 (en) Isolated mammalian monocyte cell genes; related reagents
WO2000023565B1 (en) Novel neuropilin/growth factor binding and uses thereof
JP2005518212A5 (ko)
KR970001542A (ko) 엔도글리코세라미데이즈 유전자
KR970001541A (ko) 엔도글리코세라미다아제 액티베이터를 코딩하는 유전자
KR970070198A (ko) 항-파스 재조합 항체 및 이에 대한 디엔아이

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid